CN1485072A - 治疗前列腺疾病的薏苡仁油软胶囊及其应用 - Google Patents

治疗前列腺疾病的薏苡仁油软胶囊及其应用 Download PDF

Info

Publication number
CN1485072A
CN1485072A CNA021373116A CN02137311A CN1485072A CN 1485072 A CN1485072 A CN 1485072A CN A021373116 A CNA021373116 A CN A021373116A CN 02137311 A CN02137311 A CN 02137311A CN 1485072 A CN1485072 A CN 1485072A
Authority
CN
China
Prior art keywords
soft capsule
coix seed
seed oil
oil soft
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA021373116A
Other languages
English (en)
Inventor
李大鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNA021373116A priority Critical patent/CN1485072A/zh
Priority to DE60335575T priority patent/DE60335575D1/de
Priority to AU2003272841A priority patent/AU2003272841A1/en
Priority to PCT/CN2003/000803 priority patent/WO2004028549A1/zh
Priority to RU2005112775/15A priority patent/RU2296581C2/ru
Priority to JP2004538657A priority patent/JP4718836B2/ja
Priority to ES03753221T priority patent/ES2358420T3/es
Priority to CNB038227711A priority patent/CN1301128C/zh
Priority to DK03753221.5T priority patent/DK1576959T3/da
Priority to AT03753221T priority patent/ATE493140T1/de
Priority to EP03753221A priority patent/EP1576959B1/en
Publication of CN1485072A publication Critical patent/CN1485072A/zh
Priority to US11/099,780 priority patent/US8299121B2/en
Priority to HK06104117A priority patent/HK1082426A1/xx
Priority to JP2010237581A priority patent/JP2011016852A/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8994Coix (Job's tears)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明涉及一种薏苡仁油软胶囊,主要用于治疗人体前列腺疾病。它用薏苡仁油为主料,添加抗氧剂维生素E,通过软胶囊制备工艺得到;每10000粒软胶囊中维生素E0.5~15g,注射用薏苡仁油500~10000g。本发明的薏苡仁油软胶囊,治疗人体前列腺疾病(包括癌)具有服用方便,疗效较高的特点,特别是合并注射Lupron对人体前列腺癌的生长有明显的抑制作用,抑制率为62.92%,抑瘤作用强于两药单独使用。

Description

治疗前列腺疾病的薏苡仁油软胶囊及其应用
技术领域
本发明涉及一种薏苡仁油软胶囊,主要用于治疗人体前列腺疾病。
背景技术
中国专利文献CN1029662C公开了一种“薏苡仁中性油脂及其提取方法”,提供了一种具有抗肿瘤活性,提高机体免疫功能的薏苡仁中性油脂,它主要用来制备注射液。但在现有文献中,未发现关于薏苡仁油软胶囊及其在治疗人体前列腺疾病中的应用等技术报道。
发明内容
本发明需要解决的技术问题是,提供一种治疗人体前列腺疾病的薏苡仁油软胶囊,及其应用。
本发明的治疗前列腺疾病的薏苡仁油软胶囊,用薏苡仁油为主料,添加抗氧剂维生素E,通过软胶囊制备工艺得到。具体是:每10000粒软胶囊中维生素E 0.5~15g,薏苡仁油500~10000g。其中,薏苡仁油规格可以是口服的,也可以是注射用的。
本发明的薏苡仁油软胶囊,治疗人体前列腺疾病(包括癌)具有服用方便,疗效较高的特点,特别是合并注射亮丙瑞林(商品名Lupron,通用名称Leuprolide acetate)对人体前列腺癌的生长有明显的抑制作用,抑瘤作用强于两药单独使用。
具体实施方式
下面通过实施例,对本发明的技术方案作进一步具体的说明。
制备实施例。
配料:根据处方称取薏苡仁油4500g和维生素E3.375g(抗氧剂),并将维生素E在室温下投入薏苡仁油中,搅拌溶解成一澄清、透明溶液。
溶胶:按明胶∶水∶甘油∶尼泊金乙酯(防腐剂)=1∶1∶0.4∶0.001的比例称好一定量的胶皮原料,80℃条件下搅拌化胶,减压脱气泡,60℃保温。
再通过压制,揩丸去油、烘干、整理、包装,得10000粒胶囊产品。
本发明软胶囊在治疗人体前列腺疾病中的应用有两种:一是单一口服软胶囊5~10ml/kg。另一是口服薏苡仁油软胶囊5~10ml/kg合并皮下注射Lupron 0.75~1.5mg/kg。
应用实施例1。各组取6只体重在17-18g BALB/C品系的雄性裸鼠,接种肿瘤后随机分组如下:
1)生理盐水对照组;
2)薏苡仁油软胶囊组(5ml/kg,po×10);
3)薏苡仁油软胶囊组(10ml/kg,po×10);
4)康莱特注射液组(25ml/kg,iv×10);
5)CTX(环磷酰胺)组(100mg/kg,ip×3(1,5,9))。
次日起给药,接种后21日脱颈处死动物,解剖取瘤块,比较各剂量组瘤重之大小,试验结果如下:
表1.薏苡仁油软胶囊对人体前列腺癌(PC-3M)的抑瘤作用
    组别   剂量(ml/kg) 给药方案  动物数始终   动物体重(g)始终 瘤重(g)x±SD 抑瘤率%
空白对照(生理盐水)   25   po×10   6    6   17.5  18.3  1.55±0.15
  CTX   100mg/kg   ip×3(1,5,9)   6    6   17.0  17.8  0.12±0.04** 92.47
康莱特注射液   25   iv×10   6    6   17.2  18.3  0.75±0.10** 51.61
薏苡仁油软胶囊   5   po×10   6    6   17.3  17.2  1.00±0.14** 35.48
  10   po×10   6    6   18.0  18.8  0.63±0.10** 59.14
与生理盐水组比较:**P<0.01。
从上表可见,薏苡仁油软胶囊口服10ml/kg对人体前列腺癌的生长有明显的抑制作用,抑瘤率达59.14%,优于静脉注射康莱特注射液25ml/kg的抑瘤率51.61%。
应用实施例2。各组取6只体重在19-21g BALB/C品系的雄性裸鼠,接种肿瘤后随机分组如下:
1)生理盐水对照组;
2)薏苡仁油软胶囊组(5ml/kg,po×10);
3)薏苡仁油软胶囊组(10ml/kg,po×10);
4)Lupron(0.75mg/kg,sc×1);
5)Lupron(1.50mg/kg,sc×1);
6)薏苡仁油软胶囊组(5ml/kg,po×10)+Lupron(0.75mg/kg,sc×1);
7)薏苡仁油软胶囊组(10ml/kg,po×10)+Lupron(1.50mg/kg,Sc×1)。
薏苡仁油软胶囊接种次日起给药,连续口服灌胃10次。Lupmo接种次日一次皮下注射。接种后21日脱颈处死动物,解剖取瘤块,比较各剂量组瘤重之大小。试验结果如下:
表2.薏苡仁油软胶囊对人体前列腺癌(PC-3M)的抑瘤作用
组别 剂    量(ml/kg) 给药方案 动物数始终 动物体重(g)始    终 瘤重(g)x±SD 抑瘤率%
空白对照(生理盐水)  25  po×10  6    6  19.6    22.0  1.48±0.17
薏苡仁油软胶囊  5  po×10  6    6  19.0    21.5  1.18±0.34  20.22
 5  po×10  6    6  20.0    21.8  0.82±0.12**  44.94
 Lupron  0.75  sc×1  6    6  19.8    19.8  0.93±0.23**  37.08
 1.50  sc×1  6    6  19.5    20.3  0.77±0.14**  48.31
薏苡仁油软胶囊+Lupron  5  po×10  6    6  19.7    21.3  0.63±0.16**  57.30
 0.75  sc×1
薏苡仁油软胶囊+Lupron  10  po×10  6    6  19.4    21.2  0.55±0.44**  62.92
 1.50  sc×1
与生理盐水组比较:**P<0.01。
上表表明,薏苡仁油软胶囊5、10ml/kg,连续给药10天,抑瘤率为20.22和44.94%;Lupron 0.75和1.50mg/kg皮下注射一次,抑瘤率分别为37.08和48.31%;薏苡仁油软胶囊组(5ml/kg,po×10)合并Lupron(0.75mg/kg,Sc×1)抑制率为57.30%,薏苡仁油软胶囊组(10ml/kg,po×10)合并Lupron(1.50mg/kg,Sc×1)抑制率为62.92%。试验结果表明,薏苡仁油软胶囊合并Lupron有增效作用。
研究发现,本软胶囊对前列腺肥大等其他前列腺疾病也有一定疗效。

Claims (5)

1、一种治疗前列腺疾病的薏苡仁油软胶囊,用薏苡仁油为主料,添加抗氧剂维生素E,通过软胶囊制备工艺得到。
2、根据权利要求1所述的薏苡仁油软胶囊制备工艺:每10000粒软胶囊中维生素E 0.5~15g,注射用薏苡仁油500~10000g。
3、根据权利要2所述的薏苡仁油软胶囊制备工艺:每10000粒软胶囊中维生素E3.375g,注射用薏苡仁油4500g。
4、一种薏苡仁油软胶囊在治疗前列腺疾病中的应用,软胶囊口服5~10ml/kg。
5、根据权利要求4所述的薏苡仁油软胶囊在治疗前列腺疾病中的应用,薏苡仁油软胶囊5~10ml/kg合并亮丙瑞林0.75~1.5mg/kg。
CNA021373116A 2002-09-28 2002-09-28 治疗前列腺疾病的薏苡仁油软胶囊及其应用 Pending CN1485072A (zh)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CNA021373116A CN1485072A (zh) 2002-09-28 2002-09-28 治疗前列腺疾病的薏苡仁油软胶囊及其应用
CNB038227711A CN1301128C (zh) 2002-09-28 2003-09-22 治疗前列腺疾病的薏苡仁油软胶囊
DK03753221.5T DK1576959T3 (da) 2002-09-28 2003-09-22 Softgel af NLKJ (neutrale lipider tilvejebragt fra kerner af jobstårer) til behandling af prostata sygdomme
PCT/CN2003/000803 WO2004028549A1 (fr) 2002-09-28 2003-09-22 Capsules de coixenolide destinees au traitement d'une maladie prostatique
RU2005112775/15A RU2296581C2 (ru) 2002-09-28 2003-09-22 Капсула nlkj для лечения заболеваний предстательной железы
JP2004538657A JP4718836B2 (ja) 2002-09-28 2003-09-22 前立腺疾病を治療するためのヨクイニン油軟カプセル剤
ES03753221T ES2358420T3 (es) 2002-09-28 2003-09-22 Cápsula blanda de nlkj (lípidos neutros obtenidos de semillas de lágrimas de job) para el tratamiento de enfermedades de la próstata.
DE60335575T DE60335575D1 (de) 2002-09-28 2003-09-22 Softgel enthaltend nlkj (neutrale flüssigkeiten aus den samen der hiobsträne) zur behandlung von erkrankungen der prostata
AU2003272841A AU2003272841A1 (en) 2002-09-28 2003-09-22 A coixenolide capsules for treating prostate disease
AT03753221T ATE493140T1 (de) 2002-09-28 2003-09-22 Softgel enthaltend nlkj (neutrale flüssigkeiten aus den samen der hiobsträne) zur behandlung von erkrankungen der prostata
EP03753221A EP1576959B1 (en) 2002-09-28 2003-09-22 Softgel of nlkj (neutral lipids obtained from kernels of job's tears) for treating prostate diseases
US11/099,780 US8299121B2 (en) 2002-09-28 2005-03-28 Softgel of NLKJ for treating prostate diseases
HK06104117A HK1082426A1 (en) 2002-09-28 2006-04-04 Softgel of nlkj for treating prostate disease
JP2010237581A JP2011016852A (ja) 2002-09-28 2010-10-22 前立腺疾病を治療するためのヨクイニン油軟カプセル剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA021373116A CN1485072A (zh) 2002-09-28 2002-09-28 治疗前列腺疾病的薏苡仁油软胶囊及其应用

Publications (1)

Publication Number Publication Date
CN1485072A true CN1485072A (zh) 2004-03-31

Family

ID=32034732

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA021373116A Pending CN1485072A (zh) 2002-09-28 2002-09-28 治疗前列腺疾病的薏苡仁油软胶囊及其应用
CNB038227711A Expired - Fee Related CN1301128C (zh) 2002-09-28 2003-09-22 治疗前列腺疾病的薏苡仁油软胶囊

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB038227711A Expired - Fee Related CN1301128C (zh) 2002-09-28 2003-09-22 治疗前列腺疾病的薏苡仁油软胶囊

Country Status (12)

Country Link
US (1) US8299121B2 (zh)
EP (1) EP1576959B1 (zh)
JP (2) JP4718836B2 (zh)
CN (2) CN1485072A (zh)
AT (1) ATE493140T1 (zh)
AU (1) AU2003272841A1 (zh)
DE (1) DE60335575D1 (zh)
DK (1) DK1576959T3 (zh)
ES (1) ES2358420T3 (zh)
HK (1) HK1082426A1 (zh)
RU (1) RU2296581C2 (zh)
WO (1) WO2004028549A1 (zh)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102511824A (zh) * 2011-12-20 2012-06-27 金利油脂(苏州)有限公司 一种抗突变抗肿瘤的功能性食品
CN105254498A (zh) * 2014-07-18 2016-01-20 浙江康莱特集团有限公司 化合物1,3-二油酸-2-亚油酸甘油酯、制剂、制备方法及其应用
WO2016008439A1 (zh) * 2014-07-18 2016-01-21 浙江康莱特集团有限公司 含有8种甘油三酯的薏苡仁油、制剂及其应用
WO2016008443A1 (zh) * 2014-07-18 2016-01-21 浙江康莱特集团有限公司 含有16种甘油酯的薏苡仁油、制剂及其应用
WO2016008440A1 (zh) * 2014-07-18 2016-01-21 浙江康莱特集团有限公司 含有13种甘油酯的薏苡仁油、制剂及其应用
WO2016008438A1 (zh) * 2014-07-18 2016-01-21 浙江康莱特集团有限公司 含有8种甘油三酯的药物组合物、制剂及其应用
WO2016008442A1 (zh) * 2014-07-18 2016-01-21 浙江康莱特集团有限公司 含有11种甘油三酯的薏苡仁油、制剂及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492493B2 (en) * 2003-09-22 2016-11-15 Dapeng Li Softgel of NLKJ for treating prostate diseases
BRPI0513677B8 (pt) 2004-07-30 2021-05-25 Exelixis Inc derivados de pirrol como agentes farmacêuticos

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5731604A (en) * 1980-07-31 1982-02-20 Okayasu Shoten:Kk Skin cosmetic
JPS58213719A (ja) * 1982-06-02 1983-12-12 Yasuo Araki 薬物的活性剤
JPS58210022A (ja) * 1982-06-02 1983-12-07 Yasuo Araki ハトムギ有効成分の純品精出法及び定量検定法
JPH01186815A (ja) * 1988-01-21 1989-07-26 Tokai Kapuseru Kk 軟カプセル剤およびその製造法
JPH02240019A (ja) * 1989-03-13 1990-09-25 Daicel Chem Ind Ltd 抗発癌プロモーター
JP2783848B2 (ja) * 1989-07-04 1998-08-06 晟 八木 新規ホスファチジルコリンカルシウムとその製法
CN1031261C (zh) * 1991-10-21 1996-03-13 中国科学院大连化学物理研究所 一种薏苡仁酯的提取方法
CA2125888C (en) * 1992-01-06 2002-08-27 Harry B. Demopoulos Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty
PH30249A (en) * 1992-09-16 1997-02-05 Zhejiang Provincial Hospital O Neutral lipids from endosperm of job's tears
CN1070680A (zh) * 1992-09-17 1993-04-07 李大鹏 薏苡仁中性油脂提取方法
CN1029662C (zh) 1992-09-17 1995-09-06 李大鹏 薏苡仁中性油脂及其提取方法
JPH06247858A (ja) * 1993-02-23 1994-09-06 Fujimoto Seiyaku Kk 慢性腎不全における抗骨異栄養症剤
JPH07115942A (ja) * 1993-08-09 1995-05-09 Sanji Kumai 生薬オリゴドリンク及び生薬オリゴゼリーの製造法
CN1064244C (zh) * 1993-11-09 2001-04-11 中国科学院大连化学物理研究所 中药薏苡仁提取物在制备治疗红班角化症、鳞状毛囊角化症、红皮症药物中的应用
US20010002269A1 (en) * 1997-05-06 2001-05-31 Zhao Iris Ginron Multi-phase food & beverage
CN1075378C (zh) * 1997-09-30 2001-11-28 陈金义 一种抗肿瘤的中药乳剂及其制备方法
EP1102593B1 (en) * 1998-08-03 2007-11-14 Ronald E. Wheeler Prostate formula
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
JP3983003B2 (ja) * 2001-03-15 2007-09-26 株式会社ファンケル グルタチオン増強用組成物
US20030236301A1 (en) * 2001-12-19 2003-12-25 Bob Sanders Liposomal delivery of vitamin E based compounds
CN1440782A (zh) * 2003-03-28 2003-09-10 沈阳药科大学 一种含有薏苡仁油及鸦胆子油复合纳米乳剂的制备工艺及配方

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102511824A (zh) * 2011-12-20 2012-06-27 金利油脂(苏州)有限公司 一种抗突变抗肿瘤的功能性食品
CN105254498A (zh) * 2014-07-18 2016-01-20 浙江康莱特集团有限公司 化合物1,3-二油酸-2-亚油酸甘油酯、制剂、制备方法及其应用
WO2016008439A1 (zh) * 2014-07-18 2016-01-21 浙江康莱特集团有限公司 含有8种甘油三酯的薏苡仁油、制剂及其应用
WO2016008443A1 (zh) * 2014-07-18 2016-01-21 浙江康莱特集团有限公司 含有16种甘油酯的薏苡仁油、制剂及其应用
WO2016008440A1 (zh) * 2014-07-18 2016-01-21 浙江康莱特集团有限公司 含有13种甘油酯的薏苡仁油、制剂及其应用
WO2016008438A1 (zh) * 2014-07-18 2016-01-21 浙江康莱特集团有限公司 含有8种甘油三酯的药物组合物、制剂及其应用
WO2016008442A1 (zh) * 2014-07-18 2016-01-21 浙江康莱特集团有限公司 含有11种甘油三酯的薏苡仁油、制剂及其应用
CN106413702A (zh) * 2014-07-18 2017-02-15 浙江康莱特集团有限公司 含有11种甘油三酯的薏苡仁油、制剂及其应用
CN106470680A (zh) * 2014-07-18 2017-03-01 浙江康莱特集团有限公司 含有16种甘油酯的薏苡仁油、制剂及其应用
CN106470680B (zh) * 2014-07-18 2017-09-12 浙江康莱特集团有限公司 含有16种甘油酯的薏苡仁油、制剂及其应用
CN107320469A (zh) * 2014-07-18 2017-11-07 浙江康莱特药业有限公司 一种含有16种甘油酯的薏苡仁油、制剂及其应用
AU2015291532B2 (en) * 2014-07-18 2018-03-29 Zhejiang Kanglaite Group Co., Ltd. Coix seed oil containing 16 glycerides, and pharmaceutical preparation and use thereof.
AU2015291531B2 (en) * 2014-07-18 2018-03-29 Zhejiang Kanglaite Group Co., Ltd. Coix seed oil containing 11 triglycerides, and pharmaceutical preparation and use thereof
AU2015291529B2 (en) * 2014-07-18 2018-04-19 Zhejiang Kanglaite Group Co., Ltd. Coix seed oil containing 13 glycerides, and pharmaceutical preparation and use thereof
CN107320469B (zh) * 2014-07-18 2018-12-18 浙江康莱特药业有限公司 一种含有16种甘油酯的薏苡仁油、制剂及其应用
US10314878B2 (en) 2014-07-18 2019-06-11 Zhejiang Kanglaite Group Co., Ltd. Coix seed oil containing 11 triglycerides, and pharmaceutical preparation and use thereof
EA033647B1 (ru) * 2014-07-18 2019-11-13 Zhejiang Kanglaite Group Co Ltd Масло семян коикса, содержащее 11 триглицеридов, и его фармацевтический препарат и его применение
EA033688B1 (ru) * 2014-07-18 2019-11-15 Zhejiang Kanglaite Group Co Ltd Масло семян коикса, содержащее 16 глицеридов, и его фармацевтический препарат и его применение
EA033751B1 (ru) * 2014-07-18 2019-11-21 Zhejiang Kanglaite Group Co Ltd Композиция масла семян коикса, способ ее получения и применение
US10596218B2 (en) 2014-07-18 2020-03-24 Zhejiang Kanglaite Group Co., Ltd. Coix seed oil containing 16 glycerides, and pharmaceutical preparation and use thereof

Also Published As

Publication number Publication date
CN1684697A (zh) 2005-10-19
RU2296581C2 (ru) 2007-04-10
CN1301128C (zh) 2007-02-21
DE60335575D1 (de) 2011-02-10
ATE493140T1 (de) 2011-01-15
JP4718836B2 (ja) 2011-07-06
US8299121B2 (en) 2012-10-30
HK1082426A1 (en) 2006-06-09
US20100137427A9 (en) 2010-06-03
EP1576959B1 (en) 2010-12-29
DK1576959T3 (da) 2011-03-28
EP1576959A1 (en) 2005-09-21
AU2003272841A1 (en) 2004-04-19
US20050222249A1 (en) 2005-10-06
WO2004028549A1 (fr) 2004-04-08
ES2358420T3 (es) 2011-05-10
RU2005112775A (ru) 2006-11-10
EP1576959A4 (en) 2008-04-23
JP2011016852A (ja) 2011-01-27
JP2006502193A (ja) 2006-01-19

Similar Documents

Publication Publication Date Title
Namba Maitake D-fraction: healing and preventive potential for cancer
CN1466461A (zh) 止痒性组合物和促进创伤治愈的组合物
JP2011016852A (ja) 前立腺疾病を治療するためのヨクイニン油軟カプセル剤
CN101648000B (zh) 眼镜蛇短链神经毒素在制备治疗关节炎药物中的用途
CN101049337B (zh) 一种治疗疔疖疮痈的药物及其制备方法
CN1429558A (zh) 甘露聚糖肽注射液及其制备方法和使用方法
CN102578414B (zh) 促进猪生长育肥、提高免疫力的复方蜂胶饲料添加剂及其制备方法
CN1067245C (zh) N-乙酰-d-氨基葡萄糖在制备治疗呼吸道疾病的药物中的应用
CN1217669C (zh) 柚皮苷用于制备治疗咳嗽的药物
CN1954878A (zh) 姜蒜素免疫软胶囊的制备方法
CN1826133A (zh) 治疗经化疗的癌症患者的方法
CN111558045A (zh) 一种治疗肺癌的药物组合物
CN1850149A (zh) 一种黄芪提取物与香菇多糖组成的复方制剂及其制备方法
CN110368429A (zh) 防治细菌性肠胃炎拉痢的中药组合物及其制备方法
CN1817868A (zh) 一组抗厌氧菌感染的奥硝唑类衍生物及其制备方法
CN1197615C (zh) 抗肿瘤药物及制备工艺
CN1100550C (zh) 一种适用于各种癌症的中药组合物
CN1232254C (zh) 防治仔猪和兔球虫病及菌痢病联合缓释剂及其制备方法
CN1270723C (zh) 一种阿奇霉素注射液及制备方法
CN1389265A (zh) 一种具有保健作用的中药组合物
CN1562129A (zh) 具有辅助抗癌作用的沙棘灵芝营养合剂
CN1745845A (zh) 一种抑制和治疗肿瘤的中药药物组合物及其制备方法和应用
CN102908610B (zh) 畜禽用蜂胶组合物及其制备方法
CN1895261A (zh) 商陆皂苷甲在制备类风湿性关节炎药物中的应用
CN1772268A (zh) 一种提高免疫力的药物组合物及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication